n Cardiovascular Journal of South Africa - Teveten(R) (eprosartan) reduces future risk in hypertensive stroke patients : drug trends in cardiology




Extracted from text ... The established antihypertensive agent Teveten(r) (eprosartan) has now been shown to offer effective protection against cerebrovascular and cardiovascular events in hypertensive patients with a previous stroke, over and above that offered by blood pressure reduction. Initial results from the landmark MOSES* study, presented by Professor Joachim Schrader at the XXVI Congress of the European Society of Cardiology in Munich, showed that blood pressure was equally well controlled when hypertensive patients with a history of stroke were treated with either eprosartan-based or nitrendipinebased therapies. However, there was a significant reduction of 20% in the primary endpoint (total mortality and total cardiovascular ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error